Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

2.110 +0.080 (+3.94%)
Streaming Delayed Price Updated: 3:53 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innate Pharma S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Innate Pharma to Participate in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
From Innate Pharma SA
Via Business Wire
Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023
From Innate Pharma SA
Via Business Wire
First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
From Innate Pharma SA
Via Business Wire
Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
From Innate Pharma SA
Via Business Wire
Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma
From Innate Pharma SA
Via Business Wire
Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress
From Innate Pharma SA
Via Business Wire
Why Shares of Innate Pharma Jumped Thursday
The company's collaboration agreement with Sanofi could soon pay off. 
Via The Motley Fool
SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
From Innate Pharma SA
Via Business Wire
Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023
From Innate Pharma SA
Via Business Wire
Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
From Innate Pharma SA
Via Business Wire
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Outcome of Innate Pharma’s 2023 Annual General Meeting
From Innate Pharma SA
Via Business Wire
Innate Pharma Reports First Quarter 2023 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Number of shares and voting rights of Innate Pharma as of May 1, 2023
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Conference Call and Webcast for Q1 Business Update
From Innate Pharma SA
Via Business Wire
Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting
From Innate Pharma SA
Via Business Wire
Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq
From Innate Pharma SA
Via Business Wire
Innate Pharma to Participate in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the... 
Via Benzinga
Number of Shares and Voting Rights of Innate Pharma as of April 1, 2023
From Innate Pharma SA
Via Business Wire
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023
From Innate Pharma SA
Via Business Wire
Innate Pharma Files Its 2022 Universal Registration Document (Document d’enregistrement universel) and 2022 Annual Report on Form 20-F
From Innate Pharma SA
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program
From Innate Pharma SA
Via Business Wire
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Number of Shares and Voting Rights of Innate Pharma as of March 1, 2023
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results
From Innate Pharma SA
Via Business Wire
Innate Pharma Provides Update on Silicon Valley Bank Exposure
From Innate Pharma SA
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.